nach oben

Die Innere Medizin

Erschienen in:

23.08.2018 | Paraneoplastische Syndrome | Schwerpunkt: Lunge bei Systemerkrankungen

Vaskulitiden und eosinophile Lungenerkrankungen

verfasst von: Prof. Dr. Dr. C. Kroegel, M. Foerster, S. Quickert, H. Slevogt, T. Neumann

Erschienen in: Die Innere Medizin | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eosinophile Granulozyten bilden von Th2-Lymphozyten dirigierte periphere Effektorzellen, die über die Freisetzung von zytotoxischen basischen Proteinen und Sauerstoffradikalen eine lokale Zell‑, Gewebe- und Funktionsstörung infiltrierter Organe verursachen. Zu den Eosinophilen-assoziierten Erkrankungen der Lunge gehört die eosinophile Granulomatose mit Polyangiitis (EGPA), die akute und chronische eosinophile Pneumonie und die Organmanifestation beim hypereosinophilen Syndrom oder bei bestimmten Parasitosen. In der Lunge manifestieren sich vor allem die Vaskulitiden der kleinen Gefäße (EGPA, Granulomatose mit Polyangiitis, mikroskopische Polyangiitis). Zu den mit Eosinophilie einhergehen pulmonalen Vaskulitiden gehört vor allem EGPA. Zudem gibt es verschiedene Overlap-Syndrome, bei denen EGPA-Charakteristika bei anderen ANCA-assoziierten (ANCA: antineutrophile-zytoplasmatische-Antikörper) Vaskulitiden nachzuweisen sind. Gelegentlich treten nicht-ANCA-assoziierte pulmonale Vaskulitiden mit Eosinophilen auf (z. B. Purpura Schönlein-Henoch, Kawasaki-Erkrankung, medikamenteninduzierte Hypersensitivität, paraneoplastische Syndrome). Die mit Eosinophilie einhergehenden pulmonalen Vaskulitiden werden hinsichtlich ihrer Lungen- und Eosinophilenbeteiligung dargestellt.

Nur mit Berechtigung zugänglich

Spector SL, Tan RA (2012) Is a single blood eosinophil count a reliable marker for „eosinophilic asthma?“. J Asthma 49:807–810CrossRefPubMed

Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA Jr et al (2012) Asthma outcomes: biomarkers. J Allergy Clin Immunol 129(3 Suppl):S9–S23CrossRefPubMedPubMedCentral

Price DB, Rigazio A, Campbell JD et al (2015) Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 3:849–858CrossRefPubMed

Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG (2014) Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 11:531–536CrossRefPubMed

Winkel P, Statland BE, Saunders AM, Osborn H, Kupperman H (1981) Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am J Clin Pathol 75:693–700CrossRefPubMed

Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM, Peters SP, Meyers DA, Bleecker ER, National Heart, Lung, and Blood Institute’s Severe Asthma Research Program (2013) Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 132:72–80CrossRefPubMedPubMedCentral

Diny NL, Rose NR, Čiháková D (2017) Eosinophils in autoimmune diseases. Front Immunol 8:484CrossRefPubMedPubMedCentral

McBrien CN, Menzies-Gow A (2017) The biology of eosinophils and their role in asthma. Front Med (Lausanne) 4:93. https://doi.org/10.3389/fmed.2017.00093 CrossRef

Gleich GJ, Adolphson CR (1986) The eosinophilic leukocyte: structure and function. Adv Immunol 39:177–253CrossRefPubMed

10.

Kovalszki A, Weller PF (2016) Eosinophilia. Prim Care 43:607–617CrossRefPubMedPubMedCentral

11.

Rothenberg ME (1998) Eosinophilia. N Engl J Med 338:1592–1600CrossRefPubMed

12.

Pardanani A, Patnaik MM, Tefferi A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133:468–492CrossRefPubMed

13.

Kroegel C, Costabel U (2014) Klinische Pneumologie Das Referenzwerk für Klinik und Praxis. Stuttgart, Thieme-Verlag

14.

Costabel U, Kroegel C (2016) Eosinophile Pneumonien und hypereosinophiles Syndrom. In: Kreuter M, Costabel U, Kirsten D, Herth D (Hrsg) Handbuch seltener Erkrankungen, 1. Aufl. Springer, Heidelberg, S 227–235

15.

Kroegel C, Reißig A, Mock B (2002) Eosinophilic pneumonia. Chapter 58. In: Gibson J, Geddes D, Costabel U, Sterk P (Hrsg) Respiratory medicine, 3. Aufl. Harcourt Health Science, London, New York, S 1643–1659

16.

Hellmich B, Henes J, Hetzel J (2016) Pulmonale Manifestationen von Vaskulitiden. In: Kreuter M, Costabel U, Kirsten D, Herth D (Hrsg) Handbuch seltener Erkrankungen, 1. Aufl. Springer, Heidelberg, S 91–109

17.

Nachman PH, Henderson AG (2011) Pathogenesis of lung vasculitis. Semin Respir Crit Care Med 32:245–253CrossRefPubMed

18.

Schneider HA, Yonker RA, Katz P, Longley S, Panush RS (1985) Rheumatoid vasculitis: experience with 13 patients and review of the literature. Semin Arthritis Rheum 14:280–286CrossRefPubMed

19.

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11CrossRefPubMed

20.

Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192CrossRefPubMed

21.

Tamaki H, Chatterjee S, Langford CA (2015) Eosinophilia in rheumatologic/vascular disorders. Immunol Allergy Clin North Am 35:453–476CrossRefPubMed

22.

Balding CE, Howie AJ, Drake-Lee AB, Savage CO (2001) TH2 dominance in nasal mucosa in patients with Wegener’s granulomatosis. Clin Exp Immunol 125:332–339CrossRefPubMedPubMedCentral

23.

Choopong P et al (2005) Eosinophil activation in Wegener’s granulomatosis: a harbinger of disease progression? Ocul Immunol Inflamm 13:439–445CrossRefPubMed

24.

Csernok E et al (1999) Cytokine profiles in Wegener’s granulomatosis: predominance of type 1 (TH1) in the granulomatous inflammation. Arthritis Rheum 42:742–750CrossRefPubMed

25.

Krupsky M, Landau Z, Lifschitz-Mercer B, Resnitzky P (1993) Wegener’s granulomatosis with peripheral eosinophilia. Atypical variant of a classic disease. Chest 104:1290–1292CrossRefPubMed

26.

Potter MB, Fincher RK, Finger DR (1999) Eosinophilia in Wegener’s granulomatosis. Chest 116:1480–1483CrossRefPubMed

27.

Schmitt WH, Linder R, Reinhold-Keller E, Gross WL (2001) Improved differentiation between Churg-Strauss syndrome and Wegener’s granulomatosis by an artificial neural network. Arthritis Rheum 44:1887–1896CrossRefPubMed

28.

Schnabel A, Csernok E, Braun J, Gross WL (2000) Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener’s granulomatosis. Am J Respir Crit Care Med 161:399–405CrossRefPubMed

29.

Oner T et al (2012) An observational study on peripheral blood eosinophilia in incomplete Kawasaki disease. Anadolu Kardiyol Derg 12:160–164PubMed

30.

Mullick FG, McAllister HA Jr, Wagner BM, Fenoglio JJ Jr. (1979) Drug related vasculitis. Clinicopathologic correlations in 30 patients. Hum Pathol 10:313–325CrossRefPubMed

31.

Kroegel C, Foerster M, Seeliger B, Slevogt H, Costabel U, Neumann T (2017) Eosinophile Granulomatose und Polyangiitis (Churg-Strauss-Syndrom). Pathogenetische und klinische Grundlagen, Diagnostik und Behandlungszugänge. Arzneimitteltherapie 35:413–426

32.

Neumann T, Manger B, Schmid M, Kroegel C et al (2009) Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 88:236–243CrossRef

33.

Dejaco C, Oppl B, Monach P et al (2015) Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS ONE 10(26):e121737CrossRefPubMedPubMedCentral

34.

Leavitt RY, Fauci AS (1986) Polyangiitis overlap syndrome. Classification and prospective clinical experience. Am J Med 81:79–85CrossRefPubMed

35.

Shoda H, Kanda H, Tanaka R et al (2005) Wegener’s granulomatosis with eosinophilia. Intern Med 44:750–753CrossRefPubMed

36.

Uematsu H, Takata S, Sueishi K, Inoue H (2014) Polyangiitis overlap syndrome of granulomatosis with polyangiitis (Wegener’s granulomatosis) and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). BMJ Case Rep. https://doi.org/10.1136/bcr-2013-010195 PubMedPubMedCentralCrossRef

37.

Masi AT, Hunder GG, Lie JT et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100CrossRefPubMed

38.

Rao JK, Weinberger M, Oddone EZ et al (1995) The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 123:925–932CrossRefPubMed

39.

Watts R, Lane S, Hanslik T et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227CrossRefPubMed

40.

Backman KS, Zull D, Patterson R (1995) Diagnostic complexity in a patient with asthma, pulmonary infiltrates, and eosinophilia. Ann Allergy Asthma Immunol 75:391–400PubMed

41.

Hagiwara O, Nakazawa T, Matsui S et al (1988) A case of suspected allergic granulomatous angiitis following allergic bronchopulmonary fungal disease. Nihon Kyobu Shikkan Gakkai Zasshi 26:1224–1228PubMed

42.

Hijikata H, Takemura M, Asano T et al (2014) A case of eosinophilic granulomatosis with polyangiitis associated with allergic bron-chopulmonary mycosis. Arerugi Rinsho 34:65–68

43.

Ishiguro T, Takayanagi N, Takaku Y, Kagiyama N, Kurashima K, Sugita Y (2016) Combined allergic bronchopulmonary aspergillosis and eosinophilic granulomatosis with polyangiitis: three cases and a review of the literature. Intern Med 55:793–797CrossRefPubMed

44.

Matsumoto H, Niimi A, Suzuki K et al (2000) Allergic granulomatous angiitis (Churg-Strauss syndrome) associated with allergic bronchopulmonary candidiasis. Respiration 67:577–579CrossRefPubMed

45.

Ren S (2013) Combined Churg-Strauss syndrome and allergic bronchopulmonary aspergillosis – case report and review of the literature. Clin Respir J 7:e6–e10CrossRefPubMed

46.

Stephens M, Reynolds S, Gibbs AR et al (1988) Allergic bronchopul-monary aspergillosis progressing to allergic granulomatosis and angiitis (Churg-Strauss syndrome). Am Rev Respir Dis 137:1226–1228CrossRefPubMed

47.

Henderson SR, Shah A, Copley SJ, Cook HT, Pusey CD, Salama AD, Ind PW (2016) Occam’s razor or Hickam’s dictum? Allergic bronchopulmonary aspergillosis and eosinophilic granulomatosis with polyangiitis. Thorax 71:193CrossRefPubMed

48.

Mou Y, Ye L, Ye M, Yang D, Jin M (2014) A retrospective study of patients with a delayed diagnosis of allergic bronchopulmonary aspergillosis/allergic bronchopulmonary mycosis. Allergy Asthma Proc 35:e21–e26CrossRefPubMed

49.

Della-Torre E, Lanzillotta M, Campochiaro C, Bozzalla E, Bozzolo E, Bandiera A (2016) Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: A case report and review of the literature. Medicine (Baltimore) 95(34):e4633CrossRef

50.

Danlos FX, Rossi GM, Blockmans D et al (2017) Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: a new overlap syndrome. Autoimmun Rev 16(10):1036. https://doi.org/10.1016/j.autrev.2017.07.020 CrossRefPubMed

51.

Rajagopala S, Shobha V, Devaraj U, D’Souza G, Garg I (2013) Pulmonary hemorrhage in Henoch-Schönlein purpura: case report and systematic review of the english literature. Semin Arthritis Rheum 42:391–400CrossRefPubMed

52.

Namgoong MK, Lim BK, Kim JS (1997) Eosinophil cationic protein in Henoch-Schönlein purpura and in IgA nephropathy. Pediatr Nephrol 11:703–706CrossRefPubMed

53.

Kawasaki Y, Hosoya M, Suzuki H (2005) Possible pathologenic role of interleukin-5 and eosino cationic protein in Henoch-Schönlein purpura nephritis. Pediatr Int 47:512–517CrossRefPubMed

54.

Saguil A, Fargo M, Grogan S (2015) Diagnosis and management of kawasaki disease. Am Fam Physician 91:365–371PubMed

55.

Picazo M, Fernández-Montes GJ, Molina Fábrega R, Vallcanera Calatayud A, Alabau Vázquez G, Revert Ros MA (2006) Radiologic findings in the lungs of patients with Kawasaki disease. Radiologia 48:14–18CrossRef

56.

Manganelli P, Fietta P, Carotti M, Pesci A, Salaffi F (2006) Respiratory system involvement in systemic vasculitides. Clin Exp Rheumatol 24(2 Suppl 41):S48–S59PubMed

57.

Kuo HC, Chang JC, Guo MM, Hsieh KS, Yeter D, Li SC, Yang KD (2015) Gene-gene associations with the susceptibility of Kawasaki disease and coronary artery lesions. PLoS ONE 10(11):e143056CrossRefPubMedPubMedCentral

58.

Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL (2007) The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. Pediatr Allergy Immunol 18:354–359CrossRefPubMed

59.

O’Byrne ML, Cohen MS (2013) Marked eosinophilia in a patient with history of severe atypical Kawasaki disease. Congenit Heart Dis 8:E130–E133PubMed

60.

Terai M, Yasukawa K, Honda T, Jibiki T, Hirano K, Sato J, Ishiwada N, Seguchi M, Ueda S, Kohno Y (2002) Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr Infect Dis J 21:777–781CrossRefPubMed

61.

Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 16:178–222PubMed

62.

Lin LY, Yang TH, Lin YJ, Yu HR, Yang KD, Huang YC, Chang WC, Kuo HC (2012) Comparison of the laboratory data between Kawasaki disease and enterovirus after intravenous immunoglobulin treatment. Pediatr Cardiol 33:1269–1274CrossRefPubMed

63.

Spriet S, Banks TA (2015) Drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Proc 36:501–505CrossRefPubMed

64.

Kuruvilla M, Khan DA (2016) Eosinophilic drug allergy. Clin Rev Allergy Immunol 50:228–239CrossRefPubMed

65.

Matsuno O (2012) Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 13:39. https://doi.org/10.1186/1465-9921-13-39 CrossRefPubMedPubMedCentral

66.

Bourgeois GP, Cafardi JA, Groysman V, Hughey LC (2012) A review of DRESS-associated myocarditis. J Am Acad Dermatol 66:e229–e236CrossRefPubMed

67.

Knowles SR, Shapiro LE, Shear NH (1999) Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 21:489–501CrossRefPubMed

68.

Akoun GM, Cadranel JL, Rosenow EC, Milleron BJ (1991) Bronchoalveolar lavage cell data in drug-induced pneumonit is. Allerg Immunol (Paris) 23:245–252

69.

Camus P, Fanton A, Bonniaud P, Camus C, Foucher P (2004) Interstitial lung disease induced by drugs and radiation. Respiration 71:301–326CrossRefPubMed

70.

Rich MW, Thomas RA (1997) A case of eosinophilic pneumonia and vasculitis induced by diflunisal. Chest 111:1767–1769CrossRefPubMed

71.

Bahrami S, Malone JC, Webb KG, Callen JP (2006) Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol 142:155–161CrossRefPubMed

72.

Boggess KA, Benedetti TJ, Raghu G (1996) Nitrofurantoin-induced pulmonary toxicity during pregnancy: a report of a case and review of the literature. Obstet Gynecol Surv 51:367–370CrossRefPubMed

73.

Sovijärvi AR, Lemola M, Stenius B, Idänpään-Heikkilä J (1977) Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions. Scand J Respir Dis 58:41–50PubMed

74.

Taskinen E, Tukiainen P, Sovijarvi AR (1977) Nitrofurantoin-induced alterations in pulmonary tissue. A report on five patients with acute or subacute reactions. Acta Pathol Microbiol Scand A 85:713–720PubMed

75.

Agarwal A, Agrawal A, Nathan K, Roy S (2015) Rare adverse effect of a common drug: nitrofurantoin-induced ANCA-associated vasculitis. BMJ Case Rep. https://doi.org/10.1136/bcr-2014-209253 CrossRefPubMedPubMedCentral

76.

Schatz PL, Mesologites D, Hyun J, Smith GL, Lahiri B (1989) Captopril-induced hypersensitivity lung disease. An immune-complex-mediated phenomenon. Chest 95:685–687CrossRefPubMed

77.

Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T (2014) Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol 5:197–223CrossRefPubMedPubMedCentral

78.

Nozawa K, Kaneko H, Itoh T, Katsura Y, Noguchi M, Suzuki F, Takasaki Y, Ogawa H, Takamori K, Sekigawa I (2009) Synchronous malignant B‑cell lymphoma and gastric tubular adenocarcinoma associated with paraneoplastic cutaneous vasculitis: hypereosinophilic syndrome with mixed cryoglobulinemia is an important sign of paraneoplastic syndrome. Rare Tumors 1(2):e42CrossRefPubMedPubMedCentral

79.

Lee SH, Kim JH, Park S, Won CY, Lee JH, Yi SY, Park HK, Chang SH, Jung H, Lee SS, Koo HK (2016) Pulmonary leukocytoclastic vasculitis as an initial presentation of myelodysplastic syndrome. Tuberc Respir Dis (Seoul) 79:302–306CrossRef

80.

Liu T, Cai B, Feng R (2012) Churg-Strauss syndrome presented as paraneoplastic syndrome with thymic neuroendocrine carcinoma: a case report. Rheumatol Int 32:3683–3685CrossRefPubMed

81.

Park D, Lee HJ, Lee KH, Kwon BS, Park JW, Nam KY, Lee KH (2017) Diagnosis of Churg-Strauss syndrome presented with Neuroendocrine carcinoma: a case report. Ann Rehabil Med 41:493–497CrossRefPubMedPubMedCentral

82.

Hanioka Y, Yamagami K, Yoshioka K et al (2012) Churg-Strauss syndrome concomitant with chronic symmetrical dacryoadenitis suggesting Mikulicz’s disease. Intern Med 51:2457–2461CrossRefPubMed

83.

Burton JL, Burton PA (1972) Pulmonary eosinophilia associated with vasculitis and extra-vascular granulomata. A case report and review of the literature. Br J Dermatol 87:412–419CrossRefPubMed

84.

Sekiuchi M, Nakabayashi K, Marumo T, Arimura Y, Nagasawa T, Yamada A, Fujioka Y (2005) Concurrent occurrence of allergic granulomatous angiitis and temporal arteritis: a case report and review of the literature. Mod Rheumatol 15:126–129CrossRefPubMed

85.

Sasaguri T, Soejima M, Hino Y et al (1991) Systemic necrotizing vasculitis with renal involvement accompanied by remarkable eosinophilia: a case with overlapping features of polyarteritis nodosa and allergic granulomatous angiitis. Jpn J Med 30:477–482CrossRefPubMed

86.

Fraticelli P, Kafyeke A, Mattioli M, Martino GP, Murri M, Gabrielli A (2016) Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. World J Clin Cases 4:328–332CrossRefPubMedPubMedCentral

87.

Pandit R, Scholnik A, Wulfekuhler L, Dimitrov N (2007) Non-small-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paraneoplastic syndrome. Am J Hematol 82:234–237CrossRefPubMed

88.

Verstraeten AS, De Weerdt A, van Den Eynden G, Van Marck E, Snoeckx A, Jorens PG (2011) Excessive eosinophilia as paraneoplastic syndrome in a patient with non-small-cell lung carcinoma: a case report and review of the literature. Acta Clin Belg 66:293–297PubMed

89.

Watanabe M, Ono K, Ozeki Y, Tanaka S, Aida S, Okuno Y (1998) Production of granulocyte-macrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma. Jpn J Clin Oncol 28:559–562CrossRefPubMed

Titel: Vaskulitiden und eosinophile Lungenerkrankungen
verfasst von: Prof. Dr. Dr. C. Kroegel
M. Foerster
S. Quickert
H. Slevogt
T. Neumann
Publikationsdatum: 23.08.2018
Verlag: Springer Medizin
Schlagwörter: Paraneoplastische Syndrome
Pneumonie
Leitsymptome in der Pneumologie
Mischkollagenose
Vaskulitiden
IgA-Vaskulitis
Wegener-Granulomatose
Churg-Strauss-Syndrom
Vaskulitiden
IgA-Vaskulitis
Churg-Strauss-Syndrom
Wegener-Granulomatose
Eosinophilie
Erschienen in: Die Innere Medizin / Ausgabe 9/2018
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-018-0479-1

Passend zum Thema

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

Das Niveau der postpandemischen Fallzahlen für invasive Pneumokokken-Erkrankungen (IPD) ist aus Sicht des Referenz-Zentrums für Streptokokken in Aachen alarmierend [1]. Wie sich die monatlichen IPD-Fallzahlen bei Kindern und Jugendlichen von Juli 2015 bis März 2023 entwickelt haben, lesen Sie hier.

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Auch nach dem 18. Lebensjahr kann eine HPV-Impfung sinnvoll und wichtig sein. Viele gesetzliche Krankenkassen übernehmen die Kosten auch zu einem späteren Zeitpunkt noch.

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen

Seit mehr als 130 Jahren entwickelt und produziert MSD Impfstoffe für alle Altersgruppen. Hier finden Sie nützliche Informationen und Praxismaterialien rund um das Thema Impfen.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Peranaler Blutabgang unter Antikoagulation und Thrombozytenhemmern – wie würden Sie vorgehen?

Lungenbeteiligung ist bei CED häufiger als gedacht

Die Lunge bei Systemerkrankungen

Perkutane Koronarintervention bei stabiler Angina pectoris

Drei Fälle von schwerer chronischer Diarrhö mit seltener Ursache und einfacher Therapie

CME: Palliativmedizin leicht gemacht

Passend zum Thema

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen